Editing Of Human Embryo Genes Raises Ethics Questions
By Britt E. Erickson,
Chemical & Engineering News
| 06. 29. 2015
Untitled Document
A little more than a decade after scientists first unraveled the human genome, some researchers are trying to rewrite it. Advances in gene-editing technology have provided relatively inexpensive and easy ways to delete, insert, or replace genes in human cells to correct defects associated with devastating diseases such as cystic fibrosis and sickle cell anemia. Gene-editing tools could also be used to alter plant and animal genomes to boost agricultural yields and food production or to modify insect genomes to reduce the spread of diseases such as malaria.
Not only are gene-editing tools scientifically promising, they also have the potential to be highly lucrative commercially. But with that promise comes worries that gene-editing technology could be used to create designer babies with enhanced traits, such as higher intelligence or greater beauty. Many scientists are also worried that the technology could change the human germ line—the DNA in reproductive cells that is passed on from one generation to the next—in unexpected or dangerous ways.
The ethical implications and risks of human gene editing came to a head in April...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
